Unresectable Malignant Solid Neoplasm (DBCOND0110416)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04294628	Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer	Trastuzumab deruxtecan	treatment	1	active_not_recruiting
NCT04704661	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	Ceralasertib Trastuzumab deruxtecan	treatment	1	recruiting
NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Alpelisib Binimetinib Fluorouracil Fulvestrant Hydrogen Ipatasertib Leucovorin Neratinib Nilotinib Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Selumetinib Sotorasib Sulfate ion	screening	2	recruiting
NCT05687110	Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes	Novobiocin	treatment	1	recruiting
NCT06364410	Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors	Azenosertib Trastuzumab deruxtecan	treatment	1	not_yet_recruiting
NCT04197713	Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study	Adavosertib Olaparib	treatment	1	active_not_recruiting
NCT05327010	Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial	Talazoparib	treatment	2	recruiting
NCT05554380	Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial	Ipatasertib Paclitaxel	treatment	2	recruiting
NCT05687136	Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors	Benzalkonium Nedisertib Tuvusertib	treatment	1	recruiting
NCT06626256	STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma	Aldesleukin Cyclophosphamide Fludarabine	treatment	1	not_yet_recruiting
NCT03502733	Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma	Copanlisib Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT01364051	Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies	Cediranib Hydrogen Selumetinib Sulfate ion	treatment	1	active_not_recruiting
NCT04317105	Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN	Copanlisib Ipilimumab Nivolumab	treatment	1 / 2	active_not_recruiting
NCT04514497	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer	Camptothecin Elimusertib Irinotecan Topotecan	treatment	1	active_not_recruiting
NCT03842228	Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations	Copanlisib Durvalumab Olaparib	treatment	1	active_not_recruiting
NCT04387071	CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	Vidutolimod	treatment	1 / 2	terminated
NCT03725436	ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors	Paclitaxel Sulanemadlin	treatment	1	active_not_recruiting
NCT04585958	Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer	Olaparib Trastuzumab deruxtecan	treatment	1	suspended
NCT02317874	Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer	Carboplatin Paclitaxel Talazoparib	treatment	1	completed
NCT04168320	SBRT-based PArtial Tumor Irradiation of HYpoxic Segment	No drug interventions	treatment	1	terminated
NCT01902173	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	Dabrafenib Methane Trametinib Uprosertib	treatment	1 / 2	active_not_recruiting
NCT04800627	Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor	Pembrolizumab Pevonedistat	treatment	1 / 2	terminated
NCT03872427	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	Telaglenastat	treatment	2	active_not_recruiting
NCT04007744	Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Pembrolizumab Sonidegib	treatment	1	recruiting
NCT02079740	Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	Navitoclax Trametinib	treatment	1 / 2	active_not_recruiting
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT05111561	Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	Binimetinib	treatment	1	suspended
NCT03030378	Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors	Edodekin alfa Interleukin-12 human recombinant Natural Killer Cell Pembrolizumab	treatment	1	active_not_recruiting
NCT02898207	Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer	Olaparib Onalespib	treatment	1	completed
NCT02862275	Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer	Atezolizumab	treatment	1	active_not_recruiting
NCT04729725	SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL	Cemiplimab SAR-439459	treatment	1	terminated
NCT04673448	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	Dostarlimab Niraparib	treatment	1	recruiting
NCT05803382	Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers	Capecitabine	treatment	1	recruiting
NCT02595931	M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Berzosertib Camptothecin Irinotecan	treatment	1	active_not_recruiting
NCT04266912	Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors	Avelumab Berzosertib	treatment	1 / 2	active_not_recruiting